Ozempic for Weight Loss in the UK: What It Is, Whether You Can Get It, and What Most Women Use Instead

Updated 16/07/26

‍

Ozempic has rapidly become one of the most talked-about medications in recent years, frequently appearing in news headlines and social media discussions. While its name is widely recognised, there is often confusion about its intended purpose. The primary, and crucial, approved use for Ozempic in the United Kingdom is for the management of type 2 diabetes. It is not a weight-loss drug, although weight loss can be a side effect.

The active ingredient driving its effects is called Semaglutide. This same active ingredient is also found in another medication, Wegovy, which is specifically approved for weight management. Understanding the distinction between these medications, their approved uses, and the regulatory landscape is vital for patient safety and effective treatment. This article will provide a comprehensive explanation of what Ozempic is used for, clarify its relationship with Semaglutide and Wegovy, and compare its approval status in the UK and the US. Read on to understand the precise applications and regulatory framework surrounding this significant medication.

‍

What Is Ozempic and What Is It Used For?

Ozempic is the brand name for semaglutide, a GLP-1 receptor agonist manufactured by Novo Nordisk. It was originally developed and licensed for the treatment of type 2 diabetes, where it helps lower blood sugar levels by stimulating insulin release and reducing glucose production in the liver. It's given as a once-weekly subcutaneous injection.

Semaglutide as a molecule also produces significant weight loss as a secondary effect, which is what brought it to widespread public attention. The appetite suppression and slowed gastric emptying that semaglutide causes means most people taking it eat considerably less and lose weight as a result.

That weight loss effect is why millions of people have heard of Ozempic who don't have diabetes. The cultural moment around the drug from 2022 onwards was driven almost entirely by its weight loss properties rather than its primary licensed indication. Celebrities, social media and press coverage drove demand for a medication that was, technically speaking, a diabetes drug being used off-label for weight management.

‍

Is Ozempic Available in the UK for Weight Loss?

This is where the UK picture differs significantly from what most people read about online, and it's worth being direct.

Ozempic is licensed in the UK for the treatment of type 2 diabetes. It is not licensed by the MHRA for weight management. This means that while a GP or private prescriber could technically prescribe it off-label for weight loss, it is not the standard clinical pathway and most UK providers do not prescribe it for this purpose.

The confusion arises partly because of how the drug is discussed globally, and partly because a separate medication from the same manufacturer uses the same active ingredient at a higher dose specifically for weight management. That medication is Wegovy. Wegovy is semaglutide at 2.4mg, licensed specifically for chronic weight management in the UK. Ozempic is semaglutide at a lower dose (up to 1mg), licensed for type 2 diabetes.

So when someone in the UK asks "can I get Ozempic for weight loss?" the clinically accurate answer is: not routinely, and not through NHS weight management pathways. If you are looking for semaglutide for weight loss in the UK, Wegovy is the appropriate licensed medication.

‍

What Do Women in the UK Use Instead of Ozempic for Weight Loss?

The two medications available in the UK for medically supervised weight management are Wegovy (semaglutide) and Mounjaro (tirzepatide). Both are GLP-1 receptor agonists like Ozempic, but both are licensed specifically for weight management rather than diabetes, which means they can be prescribed through weight management services including SheMed for eligible patients.

Wegovy uses the same active ingredient as Ozempic, semaglutide, at a higher dose optimised for weight loss. If you were looking for Ozempic specifically because of the semaglutide mechanism, Wegovy is the direct equivalent for weight management purposes.

Mounjaro contains tirzepatide, which activates both GLP-1 and GIP receptors rather than just GLP-1. Clinical trial data from the SURMOUNT programme consistently shows greater weight loss with tirzepatide than with semaglutide at comparable doses, which is why Mounjaro has become the more commonly prescribed option for women starting GLP-1 treatment in the UK through private providers like SheMed.

Eligibility for both medications through SheMed requires a BMI of 30 or above, or 27 or above alongside a relevant health condition. The process involves an online consultation with a clinician, blood screening

‍

Ozempic vs Mounjaro vs Wegovy: What Is the Difference?

All three are GLP-1 medications and all three cause weight loss as a primary or secondary effect. The differences are worth understanding clearly.

Ozempic contains semaglutide at doses up to 1mg and is licensed for type 2 diabetes. It produces meaningful weight loss but is not the formulation designed or licensed for that purpose in the UK.

Wegovy contains the same semaglutide molecule at a higher dose of up to 2.4mg, specifically developed and licensed for chronic weight management. The higher dose produces greater weight loss than Ozempic, which is why they are treated as separate medications despite sharing an active ingredient.

Mounjaro contains tirzepatide at doses from 2.5mg to 15mg and acts on both GLP-1 and GIP receptors simultaneously. Head-to-head clinical data from the SURMOUNT-5 trial published in 2024 found that tirzepatide produced approximately 20% greater weight loss than semaglutide at comparable doses. It is licensed in the UK for chronic weight management.

For women in the UK looking for a GLP-1 medication for weight loss, the practical choice is between Wegovy and Mounjaro. Both are available through SheMed. Your clinician can advise which is most appropriate based on your medical history, any existing conditions and your weight loss goals.

‍

‍

‍

‍

Approved Uses of Ozempic in the UK

In the United Kingdom, the Medicines and Healthcare products Regulatory Agency (MHRA) has licensed Ozempic for a single, specific purpose: the treatment of insufficiently controlled type 2 diabetes mellitus in adults as an adjunct to diet and exercise. This is a critical point to understand. Ozempic is a diabetes medication, not a weight-loss treatment.

According to the guidelines set out by the National Institute for Health and Care Excellence (NICE), which provides national guidance and advice to improve health and social care, Ozempic can be prescribed in a few different scenarios:

• As a monotherapy: It can be used on its own when metformin, the standard first-line treatment for type 2 diabetes, is considered inappropriate due to intolerance or contraindications.
• As an add-on therapy: It can be used in combination with other glucose-lowering medications when those drugs, along with diet and exercise, have not provided adequate blood sugar control.

Beyond its primary function of lowering blood sugar, significant clinical trials have demonstrated that Semaglutide offers additional health benefits. The landmark SUSTAIN-6 trial, published in The New England Journal of Medicine, found that Semaglutide significantly reduced the risk of major adverse cardiovascular events (such as heart attack, stroke, or death from cardiovascular causes) in patients with type 2 diabetes who were at high cardiovascular risk. This makes it a valuable treatment option for many individuals living with the condition, as cardiovascular disease is a common and serious complication of diabetes.

It is essential for patients to understand that Ozempic is part of a comprehensive management plan. Its effectiveness relies on being used alongside a healthy diet and regular physical activity. If you have type 2 diabetes, it is important to talk to your doctor or a diabetes specialist to determine if Ozempic is a suitable and safe option for your personal treatment plan.

‍

Ozempic vs Wegovy: What Is the Difference?

The confusion between Ozempic and Wegovy is understandable, and it comes down to one central fact: both medications contain the same active ingredient, semaglutide, but they are licensed for completely different conditions and dosed accordingly.

Ozempic is licensed for type 2 diabetes and is prescribed at doses up to 2.0mg weekly. Wegovy is licensed for chronic weight management and uses a higher target dose of 2.4mg weekly. That higher dose was not an arbitrary decision — it was specifically studied in clinical trials and approved because the greater dose produces meaningfully stronger appetite suppression and weight loss than the diabetes doses. The molecule is the same but the therapeutic application is distinct.

Who can access each medication also differs. Ozempic is prescribed to adults with type 2 diabetes as part of a diabetes management plan. Wegovy is indicated for adults with a BMI of 30 or above, or a BMI of 27 or above alongside at least one weight-related health condition such as high blood pressure, high cholesterol or type 2 diabetes.

The reason semaglutide works for both conditions comes down to how GLP-1 receptor agonists work in the body. The medication helps control blood sugar by stimulating insulin release, but it also acts on appetite-regulating centres in the brain, slows gastric emptying and reduces overall calorie intake. These effects happen regardless of the indication the medication is prescribed for, which is why the weight loss properties of Ozempic became so widely discussed even though weight management was never its licensed purpose in the UK.

Both medications work best alongside dietary changes and regular activity. They are clinically meaningful tools, but neither produces sustained results without the behavioural foundations alongside them.

‍

Frequently Asked Questions

What is Ozempic used for in the UK?

Ozempic is licensed in the UK by the MHRA for the treatment of type 2 diabetes in adults. It is not licensed for weight loss. The active ingredient, semaglutide, is available for weight management in the UK under a separate brand name, Wegovy, at a higher dose specifically approved for that purpose.

Can I get Ozempic for weight loss in the UK?

Not through standard clinical pathways. Ozempic is a diabetes medication in the UK and is not routinely prescribed for weight management. If you are looking for semaglutide for weight loss, Wegovy is the appropriate licensed medication. Mounjaro, containing tirzepatide, is also available and produces greater average weight loss in clinical trials.

Is Ozempic the same as Wegovy?

They contain the same active ingredient, semaglutide, but they are different medications with different licensed indications and doses. Ozempic is licensed for type 2 diabetes at doses up to 2.0mg weekly. Wegovy is licensed for weight management at a target dose of 2.4mg weekly. The higher dose in Wegovy was specifically studied and approved for its weight loss effects.

Is Ozempic the same as Mounjaro?

No. Ozempic contains semaglutide, which activates the GLP-1 receptor. Mounjaro contains tirzepatide, which activates both GLP-1 and GIP receptors simultaneously. Both cause weight loss, but they are different molecules with different mechanisms. Head-to-head clinical data from the SURMOUNT-5 trial found tirzepatide produced approximately 20% greater weight loss than semaglutide at comparable doses.

What are the side effects of Ozempic?

The most common side effects are gastrointestinal: nausea, vomiting, diarrhoea, abdominal pain and constipation. These typically occur when starting treatment or increasing the dose and improve as the body adjusts. More serious but less common risks include pancreatitis, gallbladder problems, kidney issues and, based on animal studies, a theoretical risk of thyroid C-cell tumours. Anyone with a personal or family history of medullary thyroid carcinoma or MEN 2 syndrome should not take semaglutide.

Is Ozempic available on the NHS?

Ozempic is available on the NHS for eligible patients with type 2 diabetes. Wegovy, the semaglutide formulation for weight loss, has more restricted NHS availability and is subject to specific NICE eligibility criteria. Access through the NHS for weight management remains limited, which is why many women access Wegovy or Mounjaro through private providers like SheMed.

What is the medical name for Ozempic?

The medical name is semaglutide. Ozempic is the brand name used for the diabetes indication. The same molecule is sold as Wegovy for weight management and as Rybelsus in an oral tablet form for type 2 diabetes.

How does Ozempic cause weight loss?

Semaglutide activates GLP-1 receptors in the brain and gut, suppressing appetite, slowing gastric emptying and reducing the reward-driven eating that drives overconsumption. Most people taking it eat considerably less without conscious restriction because hunger signals are genuinely quieter. This is why weight loss occurs even though Ozempic is not licensed for that purpose — the appetite suppression is a direct pharmacological effect of the molecule regardless of the indication it is prescribed for.

‍

References

• Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., … & Husain, M. (2016). Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. The New England Journal of Medicine, 375(19), 1834-1844.
• National Institute for Health and Care Excellence (NICE). (2023). Semaglutide for treating overweight and obesity. Technology appraisal guidance [TA875].
• National Institute for Health and Care Excellence (NICE). (2024). Type 2 diabetes in adults: management. NICE guideline [NG28].
• U.S. Food and Drug Administration (FDA). (2020). FDA approves new drug for treatment of type 2 diabetes. FDA News Release (Note: This link is illustrative of FDA announcements; specific approval letters provide detailed indications).